首页 > 市场调查报告书 > 医疗设备

体外诊断 POC诊断

市场调查报告书

商品编码

1533596

照护现场诊断市场规模、份额和成长分析：按产品类型、样本、最终用户、地区 - 产业预测，2024-2031 年

Point Of Care Diagnostics Market Size, Share, Growth Analysis, By Product Type, By Sample, By End-Users, By Region - Industry Forecast 2024-2031

出版日期: 2024年08月07日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年，全球照护现场诊断市场规模将为476.4亿美元，预测期内（2024-2031年）复合年增长率为6.1%，从2023年到2031年的505.4亿美元。年为811.7 亿美元。

照护现场诊断 (POCD) 市场是指在患者附近或患者护理点进行的医疗测试，提供通常在几分钟内完成的快速诊断，以支援分类的临床决策。该市场包括设计和製造各种诊断设备和测试，以满足各种医疗保健环境的需求，包括医院、诊所、门诊护理中心，甚至居家医疗。 POCD 具有许多优势，包括更快的周转时间、减少对中心实验室的依赖、改善病患治疗效果和成本效率。影响 POCD 市场的关键因素包括患者群体扩大、诊断材料产量增加、检测服务需求增加以及人口老化加剧。人们对该疾病早期发现和管理的认识不断提高也支持了 POCD 的发展。市场成长的主要驱动力是具有生物感测器和连接功能的手持/可携式设备的技术进步。此外，实验室晶片技术提高了就地检验的准确性、速度和可用性，进一步促进了市场扩张。 COVID-19 大流行显着加速了市场的发展，尤其是快速抗原测试和分子诊断，从而改善了病毒检测。然而，法律障碍、报销问题和品管问题等挑战可能会阻碍市场进步。儘管面临这些挑战，由于技术的不断进步、医疗保健分散化的趋势以及对个人化和高效医疗诊断的需求不断增长，全球 POCD 市场仍有望实现显着增长。

市场概况
血糖值监测产品
- 条
- 仪表
- 采血针/穿刺装置
COVID-19 检测产品
心臟代谢监测产品
- 心臟标记检测产品
- 血气/电解质检测产品
- HBA1C检测产品
传染病检查产品
- HIV检测产品
- 呼吸道传染病检查产品
- 丙型肝炎检测产品
- 医疗感染检测产品
- 流感检测产品
- 热带疾病检测产品
- 性行为感染检测产品
- 梅毒检测产品
- 梅毒检测产品
- 披衣菌感染衣原体检测产品
- 单纯疱疹病毒（HSV）检测产品
- 结核
- 困难梭状芽孢桿菌传染病检测产品
- 其他传染病检查产品
凝血监测产品
- PT/INR检测产品
- ACT/APTT测试产品
怀孕和生殖检测产品
- 妊娠测试产品
- 不孕不孕检测产品
- 肿瘤/癌症标记检测产品
- 尿液检查产品
- 胆固醇检测产品
- 血液检测产品
- 药物滥用检测产品
- 甲状腺刺激素检测产品
- 大便潜血试验产品
- 其他产品

照护现场诊断市场：依最终使用者分类

市场概况
临床实验室
门诊医疗设施/医生诊所
药局、零售诊所和电子商务平台
医院、重症监护中心、紧急护理中心
居家医疗/自我检查
其他最终用户

照护现场诊断市场规模：按地区划分

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Abbott Laboratories（US）
Siemens Healthineers AG（Germany）
Quidel Corporation（US）
F. Hoffman-La Roche Ltd.（Switzerland）
Danaher Corporation（US）
Becton, Dickinson and Company（US）
Chembio Diagnostics（US）
EKF Diagnostics（UK）
Trinity Biotech plc（Ireland）
Instrumentation Laboratory（US）
Nova Biomedical（US）
PTS Diagnostics（US）
Sekisui Diagnostics（US）
Thermo Fisher Scientific（US）
BioMerieux SA（France）
Beckman Coulter, Inc.（US）
Hologic, Inc.（US）
Cepheid（US）
Ortho Clinical Diagnostics（US）
Bio-Rad Laboratories, Inc.（US）
Trividia Health（US）
Chembio Diagnostic Systems, Inc.（US）

简介目录

Product Code: SQMIG35I2098

Global Point of Care Diagnostics Market size was valued at USD 47.64 Billion in 2022 and is poised to grow from USD 50.54 Billion in 2023 to USD 81.17 Billion by 2031, at a CAGR of 6.1% during the forecast period (2024-2031).

The Point of Care Diagnostics (POCD) market refers to medical testing conducted close to or at the site of patient care, falling under the category of rapid diagnostics typically completed within minutes to aid in clinical decision-making. This market encompasses the design and manufacturing of a variety of diagnostic equipment and assays tailored to the needs of different healthcare settings, including hospitals, clinics, ambulatory care centers, and even homecare. Point-of-care diagnostics offer numerous advantages, such as quicker turnaround times, reduced reliance on centralized laboratories, improved patient outcomes, and cost efficiency. Key factors influencing the POCD market include an expanding patient base, increased production of diagnostic materials, rising demand for laboratory services, and a growing aging population. The heightened awareness of early disease detection and management also fuels the development of POCD. A major driver of market growth is technological advancement, featuring handheld/portable devices with biosensors and connectivity capabilities. Additionally, lab-on-a-chip technology enhances the accuracy, speed, and availability of point-of-care tests, further contributing to market expansion. The COVID-19 pandemic significantly accelerated the market, particularly through rapid antigen testing and molecular diagnostics, thereby improving viral detection. However, challenges such as legal barriers, reimbursement issues, and quality control concerns could hinder market progress. Despite these challenges, the global POCD market is poised for substantial growth, driven by continuous technological advancements, the trend toward healthcare decentralization, and the increasing demand for personalized and efficient medical diagnostics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Point of Care Diagnostics (POCD) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Point of Care Diagnostics (POCD) Market Segmental Analysis

Point of care diagnostics market is segmented based on Sample, Product, End Users, and Region. Based on Sample, the market is segmented as Blood Sample, Urine Sample, Nasal and Oropharyngeal Swabs Sample, And Other Samples. Based On Product, The Market Is Further Segmented Into Glucose Monitoring Products (Strips, Meters, Lancets & Lancing Devices), Covid-19 Testing Products, Cardiometabolic Monitoring Products (Cardiac Marker Testing Products, Blood Gas/Electrolyte Testing Products, Hba1c Testing Products), Infectious Disease Testing Products (HIV Testing Products, Respiratory Infection Testing Products, Hepatitis C Testing Products, Healthcare-associated Infection Testing Products, Influenza Testing Products, Tropical Disease Testing Products, Sexually Transmitted Disease Testing Products, Syphilis Testing Products, Syphilis Testing Products, Chlamydia Trachomatis Testing Products, Herpes Simplex Virus (HSV) tEsting Products, Tuberculosis, Clostridium Difficile Infection Testing Products, Other Infectious Disease Testing Products), Coagulation Monitoring Products (PT/INR Testing Products, ACT/APTT Testing Products), Pregnancy & Fertility Testing Products (Pregnancy Testing Products, Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Product, Drugs-of-abuse Testing Products, Thyroid-stimulating Hormone Testing Products, Fecal Occult Testing Products, Other Products. Based On End Users, Point Of Care Diagnostics Market Is Further Segmented into Clinical Laboratories, Ambulatory Care Facilities and Physicians Offices, Pharmacies, Retail Clinics, And E-commerce Platforms, Hospitals, Critical Care Centers, And Urgent Care Centers, Home Care Settings And Self-testing, Other End Users. Based on region, the market is segmented into North America, Asia-Pacific, Europe, Latin America, Middle East and Africa.

Drivers of the Global Point of Care Diagnostics (POCD) Market

Globally, there has been a significant rise in the prevalence of chronic diseases such as cardiovascular issues, diabetes, and various infectious diseases. One of the key factors driving the demand for point-of-care diagnostics during the forecast period is the increasing occurrence of these disorders. According to the United Nations, approximately 38 million people were living with HIV/AIDS in 2019, including 1.8 million children and 36.2 million adults. Additionally, human respiratory syncytial virus (RSV) is a common cause of respiratory tract infections. The global adult diabetic population is projected to reach 643 million by 2030 and 783 million by 2045. The substantial increase in the prevalence of diabetes and other chronic diseases worldwide has created a demand for rapid point-of-care diagnostics aimed at effectively managing these conditions. Consequently, the market is expected to experience positive growth globally.

Restraints in the Global Point of Care Diagnostics (POCD) Market

Due to a high number of pre- and post-analytical errors, point-of-care test results often do not align accurately with central lab procedures. Pre-analytical errors can arise from unsuitable indications for performing the test, inappropriate sampling times and techniques, inadequate information about patient conditions, and other factors such as fasting before functional tests or differences in posture during similar tests. Post-analytical errors include insufficient technical validation, incorrect result assignment, and data storage issues. Point-of-care testing is frequently used in emergency situations to aid clinical decision-making, often performed by nurses or clinical team members rather than physicians. These circumstances can lead to incorrect order and result documentation, potentially resulting in misdiagnoses and affecting the quality of patient care. Due to these concerns, patients and doctors may opt against point-of-care testing. This represents one of the most significant barriers to the increased adoption of point-of-care testing.

Market Trends of the Global Point of Care Diagnostics (POCD) Market

Major market participants are increasingly focusing on integrating new technologies, such as artificial intelligence, into the production of efficient point-of-care diagnostics. Innovations like lab-on-a-chip platforms, wearable technologies, and smartphone integration have led to significant advancements in point-of-care testing devices. This trend is paving the way for future transformations, with cloud-based intelligent systems offering numerous possibilities for further revolutions. The development of new diagnostic systems has been influenced by the miniaturization of chip technology, advancements in microfluidics, and innovative biosensors. Lab-on-a-chip technology, particularly in infectious disease detection, is a key driver of POCT. This technology enables the use of microbiological culture, enzyme-linked immunosorbent assays (ELISA), and polymerase chain reaction (PCR) directly at the point of care.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Supply Chain Analysis
Ecosystem of the Market
Start-up Analysis
Patent Analysis
Case Study Analysis
Customer & Buying Criteria Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Market Attractive Index
Degree of Competition

Point of Care Diagnostic Market by Sample

Market Overview
Blood Samples
Urine Samples
Nasal & Oropharyngeal Swabs
Other Samples

Point of Care Diagnostic Market by Product

Market Overview
Glucose Monitoring Products
- Strips
- Meters
- lancets & lancing devices
Covid-19 Testing Products
Cardiometabolic Monitoring Products
- Cardiac Marker Testing Products
- Blood Gas/Electrolyte Testing Products
- HBA1C Testing Products
Infectious Disease Testing Products
- HIV Testing Products
- Respiratory Infection Testing Products
- Hepatitis C Testing Products
- Healthcare-Associated Infection Testing Products
- Influenza Testing Products
- Tropical Disease Testing Products
- Sexually Transmitted Disease Testing Products
- Syphilis testing products
- Syphilis testing products
- Chlamydia trachomatis testing products
- Herpes simplex virus (HSV) testing products
- Tuberculosis
- Clostridium Difficile Infection Testing Products
- Other Infectious Disease Testing Products
Coagulation Monitoring Products
- PT/INR Testing Products
- ACT/APTT Testing Products
Pregnancy & Fertility Testing Products
- Pregnancy Testing Products
- Fertility Testing Products
- Tumor/Cancer Marker Testing Products
- Urinalysis Testing Products
- Cholesterol Testing Products
- Hematology Testing Products
- Drugs-Of-Abuse Testing Products
- Thyroid-Stimulating Hormone Testing Products
- Fecal Occult Testing Products
- Other Products

Point of Care Diagnostic Market by End User

Market Overview
Clinical Laboratories
Ambulatory Care Facilities and Physicians Offices
Pharmacies, Retail Clinics, And E-Commerce Platforms
Hospitals, Critical Care Centers, And Urgent Care Centers
Home Care Settings and Self-Testing
Other End Users

Point of Care Diagnostic Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quidel Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffman-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chembio Diagnostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EKF Diagnostics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Trinity Biotech plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Instrumentation Laboratory (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nova Biomedical (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PTS Diagnostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sekisui Diagnostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioMerieux S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beckman Coulter, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cepheid (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ortho Clinical Diagnostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Trividia Health (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chembio Diagnostic Systems, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments